While valuations across the pharmaceutical industry have soared this year -- with shares of diversified giants like Merck (NYSE:MRK) and Pfizer up significantly -- Bristol-Myers Squibb (NYSE:BMY) in particular has been on a tear recently. In the last 12 months, its shares are up a whopping 40%. However, despite all of the promising drugs that the company is developing in clinical trials, is there any upside left in this stock today? In the following video, analysts David Williamson and Max Macaluso discuss three reasons to consider selling Bristol-Myers.
Max Macaluso and Dave Williamson
Sep 25, 2013 at 6:30PM
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs. Follow @TMFMassimo
Motley Fool Returns
Stock Advisor S&P 500
Stock Advisor launched in February of 2002. Returns as of 10/28/2020.Join Stock Advisor
Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return